A. Bondy and F. Rosa, Service d'Hépatologie et de Gastroentérologie, Centre hospitalier Intercommunal de Créteil

D. Lucidarme, . Service-d-'hépatologie, C. Gastroentérologie, . Hospitalier-de-l-'institut-catholique-lillois-thierry-fontanges, . Service-d-'hépatologie et al., Service d'Hépato-gastro-entérologie, Hôpital Tenon, Clinique du Palais

C. Pilette, C. Hospitalier, L. Mans, F. Denis, C. Hospitalier-sud-francilien et al., Service d'Anatomo-Pathologie, Hôpital Beaujon, Clinique Ambroise Paré Sciences Humaines et Sociales, INSERM

C. Dorival-mouly, I. Umr-s, C. Estes, S. Blach, K. Razavi-shearer et al., Cécilie Dufour, INSERM UMR-S 1136 Céline Fréhaut, INSERM UMR-S 1136 Aurélie Lesel, INSERM UMR-S 1136 Global epidemiology and genotype distribution of the hepatitis C virus infection, Nathalie Zahraa, INSERM UMR-S J Hepatol, vol.6, issue.611, pp.45-57, 1136.

M. Fried, M. Shiffman, K. Reddy, C. Smith, G. Marinos et al., Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection, New England Journal of Medicine, vol.347, issue.13, pp.975-82, 2002.
DOI : 10.1056/NEJMoa020047

M. Manns, J. Mchutchison, S. Gordon, V. Rustgi, M. Shiffman et al., Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-65, 2001.
DOI : 10.1016/S0140-6736(01)06102-5

D. Ge, J. Fellay, A. Thompson, J. Simon, K. Shianna et al., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009.
DOI : 10.1038/nature08309

J. Casanova and L. Abel, The Genetic Theory of Infectious Diseases: A Brief History and Selected Illustrations, Annual Review of Genomics and Human Genetics, vol.14, issue.1, pp.215-258, 2013.
DOI : 10.1146/annurev-genom-091212-153448

L. Prokunina-olsson, B. Muchmore, W. Tang, R. Pfeiffer, H. Park et al., A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus, Nature Genetics, vol.29, issue.2, pp.164-71, 2013.
DOI : 10.1073/pnas.96.19.10800

J. Fellay, A. Thompson, D. Ge, C. Gumbs, T. Urban et al., ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature, Mar, vol.18, issue.4647287, pp.405-413, 2010.

B. Bacon, S. Gordon, E. Lawitz, P. Marcellin, J. Vierling et al., Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.364, issue.13, pp.1207-1224, 2011.
DOI : 10.1056/NEJMoa1009482

S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago et al., Telaprevir for Retreatment of HCV Infection, New England Journal of Medicine, vol.364, issue.25, pp.2417-2445, 2011.
DOI : 10.1056/NEJMoa1013086

C. Hézode, H. Fontaine, C. Dorival, D. Larrey, F. Zoulim et al., Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) ??? NCT01514890, Journal of Hepatology, vol.59, issue.3, pp.434-475, 2013.
DOI : 10.1016/j.jhep.2013.04.035

S. Zeuzem, I. Jacobson, T. Baykal, R. Marinho, F. Poordad et al., Retreatment of HCV with ABT-450/r???Ombitasvir and Dasabuvir with Ribavirin, New England Journal of Medicine, vol.370, issue.17, pp.1604-1618, 2014.
DOI : 10.1056/NEJMoa1401561

C. Hézode, H. Fontaine, C. Dorival, F. Zoulim, D. Larrey et al., Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis, Gastroenterology, vol.147, issue.1, p.24704719
DOI : 10.1053/j.gastro.2014.03.051

P. Sultanik, V. Mallet, S. Lagaye, A. Casrouge, C. Dorival et al., Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy, Liver International, vol.33, issue.7, 2015.
DOI : 10.1111/liv.12759
URL : https://hal.archives-ouvertes.fr/pasteur-01380846

M. Cassader, G. Ruiu, R. Gambino, F. Guzzon, A. Pagano et al., Influence of apolipoprotein H polymorphism on levels of triglycerides, Atherosclerosis, vol.110, issue.1, pp.45-51, 1994.
DOI : 10.1016/0021-9150(94)90066-3

M. Shipkova, K. Lorenz, M. Oellerich, E. Wieland, N. Ahsen et al., Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population, Clinical Chemistry, vol.52, issue.2, pp.240-247, 2006.
DOI : 10.1373/clinchem.2005.059501

H. Mehdi, S. Manzi, P. Desai, Q. Chen, C. Nestlerode et al., A functional polymorphism at the transcriptional initiation site in beta2-glycoprotein I (apolipoprotein H) associated with reduced gene expression and lower plasma levels of beta2-glycoprotein I, European Journal of Biochemistry, vol.42, issue.2, pp.230-238, 2003.
DOI : 10.1016/S0378-1119(96)00438-6

S. Suresh, F. Demirci, E. Jacobs, A. Kao, E. Rhew et al., Apolipoprotein H Promoter Polymorphisms in Relation to Lupus and Lupus-related Phenotypes, The Journal of Rheumatology, vol.36, issue.2, pp.315-337, 2009.
DOI : 10.3899/jrheum.080482

G. Athanasiadis, M. Sabater-lleal, A. Buil, J. Souto, M. Borrell et al., -glycoprotein??I levels: a genome-wide association study in extended pedigrees from Spain, Journal of Thrombosis and Haemostasis, vol.82, issue.3, pp.521-529
DOI : 10.1111/jth.12120
URL : https://hal.archives-ouvertes.fr/hal-00552407

M. Leduc, L. Shimmin, K. Klos, C. Hanis, E. Boerwinkle et al., Comprehensive evaluation of apolipoprotein H gene (APOH) variation identifies novel associations with measures of lipid metabolism in GENOA, The Journal of Lipid Research, vol.49, issue.12, pp.2648-56, 2008.
DOI : 10.1194/jlr.M800155-JLR200

H. Mehdi, C. Aston, D. Sanghera, R. Hamman, and M. Kamboh, Genetic variation in the apolipoprotein H (beta2-glycoprotein I) gene affects plasma apolipoprotein H concentrations, Hum Genet, vol.105, issue.12, pp.63-71, 1999.

F. Poordad, J. Bronowicki, S. Gordon, S. Zeuzem, I. Jacobson et al., Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir, Gastroenterology, vol.143, issue.3, pp.608-626, 2012.
DOI : 10.1053/j.gastro.2012.05.011
URL : https://hal.archives-ouvertes.fr/hal-00866794

S. Pol, J. Aerssens, S. Zeuzem, P. Andreone, E. Lawitz et al., Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure, Journal of Hepatology, vol.58, issue.5, pp.883-892
DOI : 10.1016/j.jhep.2012.12.023

J. Holmes, P. Desmond, and A. Thompson, Does IL28B genotyping still have a role in the era of directacting antiviral therapy for chronic hepatitis C infection? J Viral Hepat, pp.677-84, 2012.

K. Chayama, C. Hayes, H. Abe, D. Miki, H. Ochi et al., IL28B But Not ITPA Polymorphism Is Predictive of Response to Pegylated Interferon, Ribavirin, and Telaprevir Triple Therapy in Patients With Genotype 1 Hepatitis C, Journal of Infectious Diseases, vol.204, issue.1, pp.84-93, 2011.
DOI : 10.1093/infdis/jir210

N. Akuta, F. Suzuki, T. Fukushima, Y. Kawamura, H. Sezaki et al., Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1, Journal of Clinical Microbiology, vol.51, issue.9, pp.2862-2870, 2013.
DOI : 10.1128/JCM.01129-13

A. Tsubota, N. Shimada, M. Atsukawa, H. Abe, K. Kato et al., polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b, Journal of Gastroenterology and Hepatology, vol.55, issue.1, pp.144-50, 2014.
DOI : 10.1111/jgh.12402

R. Sterling, A. Kuo, V. Rustgi, M. Sulkowski, T. Stewart et al., Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir, Alimentary Pharmacology & Therapeutics, vol.38, issue.Suppl. 1, pp.671-85
DOI : 10.1111/apt.13095

N. Shimada, A. Tsubota, M. Atsukawa, H. Abe, T. Ide et al., A 48-week telaprevir-based triple combination therapy improves sustained virological response rate in previous non-responders to peginterferon and ribavirin with genotype 1b chronic hepatitis C: A multicenter study, Hepatology Research, vol.146, issue.14, 2014.
DOI : 10.1111/hepr.12323

A. Thompson, J. Fellay, K. Patel, H. Tillmann, S. Naggie et al., Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia and Decrease the Need for Ribavirin Dose Reduction, Gastroenterology, vol.139, issue.4, pp.1181-1190, 2010.
DOI : 10.1053/j.gastro.2010.06.016

F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, M. Hirakawa et al., Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatol Baltim Md, Feb, vol.53, issue.2, pp.415-436, 2011.

A. Eskesen, E. Melum, A. Moghaddam, K. Bjøro, H. Verbaan et al., Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort, European Journal of Gastroenterology & Hepatology, vol.24, issue.8, pp.890-896, 2012.
DOI : 10.1097/MEG.0b013e3283546efd

M. Rau, F. Stickel, S. Russmann, C. Manser, P. Becker et al., Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection, J Hepatol. 2013, vol.58, issue.4, pp.669-75

W. Ahmed, N. Furusyo, S. Zaky, A. Eldin, H. Aboalam et al., Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients, World Journal of Gastroenterology, vol.19, issue.9
DOI : 10.3748/wjg.v19.i9.1387